Related Experiment Video
Updated: Sep 21, 2025
10:21
Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
Published on: September 12, 2019
7.3K
Cyclin-dependent Kinase 9 as a Potential Target for Anti-TNF-resistant Inflammatory Bowel Disease
Omer S Omer1, Arnulf Hertweck2, Luke B Roberts3
1School of Immunology and Microbial Sciences, King's College London, London, UK; National Institute for Health Research Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College, London, UK.
Summary
Targeting CDK9, a factor downstream of T-bet, offers a new strategy for inflammatory bowel disease (IBD). This approach suppresses key inflammatory genes in T cells, showing promise for anti-TNF-resistant IBD patients.
Area of Science:
- Immunology
- Molecular Biology
- Gastroenterology
Background:
- Inflammatory bowel disease (IBD) poses challenges, particularly resistance to anti-tumor necrosis factor (TNF) therapies.
- The transcription factor T-bet regulates intestinal homeostasis and pro-inflammatory cytokines like TNF and interferon (IFN)-γ.
- Targeting T-bet's function is a potential therapeutic strategy for IBD, but direct targeting remains difficult.
Purpose of the Study:
- To investigate the therapeutic potential of inhibiting T-bet's transactivation function using P-TEFb (CDK9-cyclin T) inhibitors.
- To evaluate the effects of cyclin-dependent kinase 9 (CDK9) inhibitors on cytokine production and gene expression in colonic CD4+ T cells from IBD patients.
- To link CDK9 inhibition-affected genetic pathways to clinical response in IBD.
Main Methods:
- Utilized an adaptive immune-mediated colitis model.
- Analyzed human colonic lymphocytes from IBD patients.
- Examined gene expression and cytokine production in colonic CD4+ T cells.
- Correlated genetic findings with clinical datasets.
Main Results:
- Systemic CDK9 inhibition improved colitis histology and suppressed colonic CD4+ T cell-derived IFN-γ and IL-17A.
- CDK9 inhibition repressed pro-inflammatory genes in IBD lymphocytes, particularly those regulated by T-bet.
- CDK9 inhibition targeted genes highly expressed in anti-TNF resistant IBD and predicted non-response to anti-TNF therapy.
Conclusions:
- CDK9 is identified as a promising therapeutic target for anti-TNF-resistant IBD.
- Inhibiting CDK9 demonstrates potential for clinical translation in treating refractory IBD.
- Targeting CDK9 offers a novel approach to managing inflammatory bowel disease.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
243
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
243
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
278
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
278
01:29Inflammatory Bowel Disease IV: Pharmacological Management
205
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
205
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
212
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
212
02:34Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
02:26NF-κB-dependent Signaling Pathway
7.9K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.9K